Logo image of CURI

CURIOSITYSTREAM INC (CURI) Stock Fundamental Analysis

NASDAQ:CURI - US23130Q1076 - Common Stock

4.49 USD
+0.03 (+0.67%)
Last: 9/3/2025, 8:07:58 PM
4.49 USD
0 (0%)
After Hours: 9/3/2025, 8:07:58 PM
Fundamental Rating

4

CURI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 79 industry peers in the Entertainment industry. The financial health of CURI is average, but there are quite some concerns on its profitability. CURI is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CURI has reported negative net income.
CURI had a positive operating cash flow in the past year.
CURI had negative earnings in each of the past 5 years.
In the past 5 years CURI reported 4 times negative operating cash flow.
CURI Yearly Net Income VS EBIT VS OCF VS FCFCURI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CURI has a Return On Assets of -6.07%. This is in the lower half of the industry: CURI underperforms 63.29% of its industry peers.
CURI has a Return On Equity (-9.57%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -6.07%
ROE -9.57%
ROIC N/A
ROA(3y)-32.15%
ROA(5y)-36.84%
ROE(3y)-44.33%
ROE(5y)-58.97%
ROIC(3y)N/A
ROIC(5y)N/A
CURI Yearly ROA, ROE, ROICCURI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of CURI (53.07%) is better than 62.03% of its industry peers.
CURI's Gross Margin has been stable in the last couple of years.
CURI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.26%
GM growth 5YN/A
CURI Yearly Profit, Operating, Gross MarginsCURI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

CURI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CURI has been increased compared to 1 year ago.
Compared to 5 years ago, CURI has more shares outstanding
There is no outstanding debt for CURI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CURI Yearly Shares OutstandingCURI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CURI Yearly Total Debt VS Total AssetsCURI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CURI has an Altman-Z score of 0.46. This is a bad value and indicates that CURI is not financially healthy and even has some risk of bankruptcy.
CURI has a Altman-Z score (0.46) which is comparable to the rest of the industry.
CURI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 0.46
ROIC/WACCN/A
WACC8.87%
CURI Yearly LT Debt VS Equity VS FCFCURI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

CURI has a Current Ratio of 1.66. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.66, CURI is in the better half of the industry, outperforming 67.09% of the companies in the same industry.
CURI has a Quick Ratio of 1.66. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CURI (1.66) is better than 69.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
CURI Yearly Current Assets VS Current LiabilitesCURI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

CURI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.50%, which is quite impressive.
The Revenue has grown by 11.02% in the past year. This is quite good.
Measured over the past years, CURI shows a very negative growth in Revenue. The Revenue has been decreasing by -10.47% on average per year.
EPS 1Y (TTM)87.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
Revenue 1Y (TTM)11.02%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%53.38%

3.2 Future

CURI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.40% yearly.
Based on estimates for the next years, CURI will show a quite strong growth in Revenue. The Revenue will grow by 13.02% on average per year.
EPS Next Y97.17%
EPS Next 2Y48.74%
EPS Next 3Y33.56%
EPS Next 5Y50.4%
Revenue Next Year33.49%
Revenue Next 2Y22.11%
Revenue Next 3Y18.56%
Revenue Next 5Y13.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CURI Yearly Revenue VS EstimatesCURI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
CURI Yearly EPS VS EstimatesCURI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CURI. In the last year negative earnings were reported.
CURI is valuated quite expensively with a Price/Forward Earnings ratio of 88.04.
The rest of the industry has a similar Price/Forward Earnings ratio as CURI.
CURI is valuated expensively when we compare the Price/Forward Earnings ratio to 22.48, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 88.04
CURI Price Earnings VS Forward Price EarningsCURI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CURI is valued a bit cheaper than 64.56% of the companies in the same industry.
CURI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CURI is cheaper than 79.75% of the companies in the same industry.
Industry RankSector Rank
P/FCF 26.2
EV/EBITDA 20.51
CURI Per share dataCURI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CURI's earnings are expected to grow with 33.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.74%
EPS Next 3Y33.56%

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 7.27%, CURI is a good candidate for dividend investing.
The stock price of CURI dropped by -20.53% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
CURI's Dividend Yield is rather good when compared to the industry average which is at 6.42. CURI pays more dividend than 94.94% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, CURI pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.27%

5.2 History

CURI is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
CURI Yearly Dividends per shareCURI Yearly Dividends per shareYearly Dividends per share 2024 2025 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

CURI has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-322.61%
EPS Next 2Y48.74%
EPS Next 3Y33.56%
CURI Yearly Income VS Free CF VS DividendCURI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

More info and screens

CURIOSITYSTREAM INC

NASDAQ:CURI (9/3/2025, 8:07:58 PM)

After market: 4.49 0 (0%)

4.49

+0.03 (+0.67%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners13.6%
Inst Owner Change65.24%
Ins Owners6.96%
Ins Owner Change2.23%
Market Cap260.11M
Analysts84.44
Price Target6.29 (40.09%)
Short Float %4.11%
Short Ratio2.2
Dividend
Industry RankSector Rank
Dividend Yield 7.27%
Yearly Dividend0.07
Dividend Growth(5Y)N/A
DP-322.61%
Div Incr Years1
Div Non Decr Years1
Ex-Date09-05 2025-09-05 (0.08)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)6.66%
Min Revenue beat(2)-0.09%
Max Revenue beat(2)13.4%
Revenue beat(4)2
Avg Revenue beat(4)1.87%
Min Revenue beat(4)-9.67%
Max Revenue beat(4)13.4%
Revenue beat(8)3
Avg Revenue beat(8)0.63%
Revenue beat(12)6
Avg Revenue beat(12)-2.69%
Revenue beat(16)7
Avg Revenue beat(16)-2.52%
PT rev (1m)9.07%
PT rev (3m)107.14%
EPS NQ rev (1m)12.5%
EPS NQ rev (3m)12.5%
EPS NY rev (1m)74.99%
EPS NY rev (3m)89.74%
Revenue NQ rev (1m)12.07%
Revenue NQ rev (3m)16.64%
Revenue NY rev (1m)7.53%
Revenue NY rev (3m)7.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 88.04
P/S 4.28
P/FCF 26.2
P/OCF 25.99
P/B 5.22
P/tB 12.23
EV/EBITDA 20.51
EPS(TTM)-0.09
EYN/A
EPS(NY)0.05
Fwd EY1.14%
FCF(TTM)0.17
FCFY3.82%
OCF(TTM)0.17
OCFY3.85%
SpS1.05
BVpS0.86
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.07%
ROE -9.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.07%
FCFM 16.32%
ROA(3y)-32.15%
ROA(5y)-36.84%
ROE(3y)-44.33%
ROE(5y)-58.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.26%
GM growth 5YN/A
F-Score7
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.47%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion 98.19%
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 0.46
F-Score7
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)0.12%
Cap/Depr(5y)1.04%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125%
EPS Next Y97.17%
EPS Next 2Y48.74%
EPS Next 3Y33.56%
EPS Next 5Y50.4%
Revenue 1Y (TTM)11.02%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%53.38%
Revenue Next Year33.49%
Revenue Next 2Y22.11%
Revenue Next 3Y18.56%
Revenue Next 5Y13.02%
EBIT growth 1Y57.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.08%
EBIT Next 3Y51.16%
EBIT Next 5Y26.01%
FCF growth 1Y131.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y131.29%
OCF growth 3YN/A
OCF growth 5YN/A